Salmeterol

When ATH:
R03AC12

Characteristic.

White or off-white powder, easily soluble in methanol, slightly soluble in ethanol, chloroform and isopropanol, sparingly soluble in water.

Pharmacological action.
Anti-asthma, bronchodilatory.

Application.

Reversible airway obstruction: bronchial asthma (prevention of bronchospasm, provoked by exercise or nocturnal asthma attacks), chronic bronchitis.

Contraindications.

Hypersensitivity, pregnancy, lactation, childhood (to 12 years).

Pregnancy and breast-feeding.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects.

Paradoxical bronchospasm (It requires discontinuation), tachycardia, headache, tremor, nervousness, diarrhea, stomach ache, nausea, viral gastroenteritis, kaliopenia; Local reactions: rhinitis, laringit, irritation, itching.

Cooperation.

MAO inhibitors and tricyclic depressants potentiate the effects on the cardiovascular system. Xanthine derivatives, glucocorticoids and diuretics increase the risk of hypokalemia, especially in patients with severe asthma, as well as under conditions of hypoxia (mandatory monitoring of potassium level in the blood plasma). Compatible (possible simultaneous inhaled corticosteroid and / or an acid kromoglitsievoy.

Overdose.

Symptoms: tachycardia and / or arrhythmia, headache, tremor, hypokalemia and hyperglycemia.

Treatment: transition to alternative drugs, introduction of cardioselective beta-blockers.

Dosing and Administration.

Inhalation. For the prevention of asthma attacks, incl. night, The usual dose for adults and children over 12 years - 2 inhalation (50 g) twice a day (in the morning and in the evening).

For the prevention of bronchospasm, provoked by physical activity - 2 inhalation at least 30-60 minutes before exercise. In the treatment of severe bronchial asthma - according to 100 g 2 once a day.

Precautions.

Not available for the relief of bronchospasm. With care prescribe a drug to patients with thyrotoxicosis, patients with severe asthma, during hypoxia of any origin.

The therapeutic effect may be reduced while cooling the inhaler.

If the recommended doses are not effective, need to increase their. It will be appreciated, that the regular use of salmeterol in most patients usually decreases the need for additional use of short-sympathomimetic.

Should not enter the spray into the eyes.

Cooperation

Active substance	Description of interaction
Akarʙoza	FMR: antagonizm. Against the background of the effect of salmeterol attenuated; the combined appointment is necessary to monitor the concentration of glucose in the blood.
Aminofillin	FMR: synergism. It increases the risk of hypokalemia.
Atenolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Aцetazolamid	FMR. Increases (mutually) the risk of hypokalemia.
Betaksolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Bisoprolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Bumetanid	FMR: synergism. Increases (mutually) the risk of hypokalemia.
Glipizide	FMR: antagonizm. Against the background of the effect of salmeterol attenuated; the combined appointment is necessary to monitor the concentration of glucose in the blood.
Digoxin	FMR: synergism. Against the background of salmeterol increased risk of cardiac arrhythmias.
Clomipramine	FMR: synergism. Enhancing effect on the cardiovascular system.
Cromoglicic acid	FMR: synergism. Do effect.
Levothyroxine sodium	FMR: synergism. Strengthens (mutually) effect. Against the background of salmeterol increased risk of coronary heart disease in patients with coronary artery disease.
Linezolid	FMR: synergism. As MAO inhibitor increases the likelihood of adverse effects on the cardiovascular system.
Maprotilin	FMR: synergism. Enhancing effect on the cardiovascular system.
Metoprolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Moclobemide	FMR: synergism. As MAO inhibitor may potentiate the cardiovascular system.
Nadolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Pindolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Procarbazine	FMR: synergism. As MAO inhibitor may enhance the effect on the cardiovascular system.
Propranolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Repaglinide	FMR: antagonizm. Against the background of the effect of salmeterol attenuated; the combined appointment is necessary to monitor the concentration of glucose in the blood.
Selegiline	FMR: synergism. As MAO inhibitor enhances the effect on the cardiovascular system.
Sotalol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Timolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Furosemid	FMR: synergism. Increases (mutually) the risk of hypokalemia.
Esmolol	FMR: antagonizm. Weakens effect; may cause bronchospasm in patients with asthma.
Ethacrynic acid	FMR. Increases (mutually) the risk of hypokalemia.